Introduction
Pancreatic adenocarcinoma is the fifth leading cause of cancer death in the western world. Its management is complicated by the difficulty of diagnosis and poor response to conventional therapies. Despite recent progress in elucidating the molecular genetics of this malignancy (Hruban et al., 2000; Moore et al., 2001) , further studies are clearly needed in order to find new molecular markers for diagnostic and prognostic purposes.
Pancreatic ductal adenocarcinoma typically presents as a solid mass characterized by a highly desmoplastic stromal reaction with usually only a low percentage of tumour cells (540%). Normal ductal epithelial cells comprise less than 5% of the total population of cells making up this organ and are considered to be the normal counterpart of pancreatic adenocarcinoma cells. This greatly hampers comparative gene expression studies and necessitates selective procurement of both normal and malignant ductal epithelial cells from within complex tissues. Laser capture microdissection (LCM) is a recently described method for isolating pure cell populations (Bonner et al., 1997; Sirivatanauksorn et al., 1999) . We have used a Pixcell II system (Arcturus, Sunnyvale, USA) to obtain pure neoplastic and normal duct cells in order to investigate the molecular changes that accompany malignant transformation of this epithelial tumour type. Gene expression profiles of such samples were analysed utilizing Atlas cancer cDNA arrays containing 588 cancer-related genes spotted in duplicate (http://www.clontech.com/atlas/genelists/).
Tissue arrays have recently been described as a highthroughput method to extend and validate gene expression data and to aid in the identification of new molecular markers in various malignancies (Kallioniemi et al., 2001) . With the same aim, we have constructed a pancreatic tissue array and used it to verify protein expression of several genes whose dysregulation was implicated by cDNA arrays.
Results

Gene expression data
Laser capture microdissection of tumour cells and normal ductal epithelial cells from corresponding tissue blocks distant from the malignant lesion was performed. Ducts from corresponding normal tissue blocks showed no evidence of dysplasia, except for case no. 2 in which there was severe dysplasia restricted to the main duct. Careful microdissection of smaller ducts therefore had to be performed to this case (data not shown). Also, there was no evidence of pancreatitis in corresponding normal sections in any of the three cases analysed. The RNA isolated from normal tissues was the same quality as the RNA of microdissected tumour cells shown in Figure 1 .
DNA mutation analysis of the three cases showed a similar pattern of mutations, including mutation of KRAS, homozygous deletion of CDKN2, and no alteration in the tumour suppression genes TP53 and MADH4 (Table 1) .
'SMART'-amplified and labelled cDNAs were applied to Atlas cDNA arrays and the results are summarized in Table 2 , where only the 15 genes that showed a consistent expression change in both replicates of the experiment were included.
Confirmation of differential expression
Out of 15 differentially expressed genes, 11 were upregulated and four downregulated. The upregulation of six genes was confirmed by exploring publicly available DDD and SAGEmap data (see under 'Confirmation' in Table 2 ).
Analysis of DDD data showed that collagen type I was upregulated in pancreatic carcinoma when compared to normal pancreas (P50.05). SAGE data show statistically significant upregulation of GAPDH (Hs.169476, tag: gcctccaagg) in the CAPAN1 cell line and both pancreatic adenocarcinoma samples (P50.01). CD59 (Hs.119663; tag: tgactggcag) was present in three cell lines, both tumour samples and one of the normal ductal cell libraries (SAGEHX), but the increased expression only reached statistical significance (P=0.03) in the Panc1 cell line. MMP7 (Hs.2256; tag: aacttggcca) was represented with only one tag in the SAGEHX library constructed from Figure 2a ). The upregulation of two genes that were not present in the SAGEmap database, ABL2 and Notch4, was also confirmed by QRT -PCR. The level of ABL2 RNA was increased more than twofold in 11 of 16 pancreatic cancer cell lines (70%) in comparison to the mean expression level of seven normal pancreatic samples. The highest upregulation of ABL2 was a 21-fold increase in the 8988t cell line, as shown in Figure 2b . The QRT -PCR data for expression of the Notch4 gene are shown in Figure  2c , where it is evident that around 60% of pancreatic cancer cell lines displayed higher than twofold upregulation of the Notch4 transcript. QRT -PCR with the appropriate primer pairs for each of the three genes was also performed on a panel of 20 primary pancreatic adenocarcinoma specimens and the percentage of tumours that had more than twofold increase in the transcript number was 20, 30 and 50% for SOD1, ABL2 and Notch4 respectively (data not shown). This relatively modest and variable upregulation of SOD1 and ABL2 in bulk tissues is highly likely to be a reflection of a variable content of tumour cells within a complex tissue matrix, while upregulation of Notch4 transcripts in half of the bulk tumours suggests shared expression in both tumour cells and desmoplastic stroma. Figure 3 shows TMA with 110 tissue biopsies, including 15 normal and 95 neoplastic pancreatic samples that were used to assess at the protein level the differential expression of the upregulated CD59 gene and the downregulated XRCC1 gene. Figure 3b and c show representative images of two core biopsies comprising normal and malignant pancreatic tissues respectively, immunostained with anti-CD59 antibody. Moderate immunoreactivity was detected in both ductal and acinar elements of the normal exocrine pancreas, as well as in the islets. However, much stronger cytoplasmic staining of malignant ducts, in some cases with luminal accentuation, was observed in almost 60% of the tumour cases. This difference in CD59 protein expression between malignant and normal ducts was statistically significant (P=0.0137, Table 3 ).
TMA and immunohistochemical analysis
The reduced expression of XRCC1 seen in microarray analysis was confirmed by reduced immunoreactivity in 75% of cancer samples when compared to the strong nuclear and cytoplasmic immunoreactivity found in the majority of epithelial cells in the non-neoplastic pancreas (P=0.0134) (Table 3, Figure 3d , e). Confirmation indicates the independent method that confirmed upregulation or down-regulation of the gene: SAGE, serial analysis of gene expression; QT -PCR, quantitative reverse transcription -polymerase chain reaction; DDD, differential display; IHC, immunohistochemistry; n.c., not confirmed; SKY, spectral karyotyping analysis
Discussion
Gene expression analysis in complete pancreatic tissue is compromised by the paucity of neoplastic cells within the tumour mass, which is usually characterized by a highly abundant stromal reaction. Although we achieved enrichment to more than 95% of tumoral cell content in samples by fine needle aspirations (Crnogorac-Jurcevic et al., 2001 ) this procedure is not suitable for obtaining enriched populations of normal duct epithelium, which is considered the normal counterpart of pancreatic ductal cancer cells. LCM of both normal ducts and malignant epithelium from the same patient was therefore performed and 15 differentially expressed genes were identified by cDNA array analysis of such material. As the results are obtained from a limited number of dissected cases due to the exclusion of the majority of other specimens which either suffered from low RNA quality after LCM, or had an insufficient quantity of control RNA from microdissected matched normal ducts, candidate genes were further explored by several independent methods and on a larger number of samples.
SAGE and DDD data available online were mostly in agreement with our cDNA array data, except for TIMP1 which appears under-represented in the pancreatic cancer SAGE libraries (average tag number/million in four pancreatic cell lines and two cancer tissues were 116 and 461, respectively, in comparison to 712 tags per million in normal pancreatic ducts). As upregulation of TIMP1 in pancreatic adenocarcinomas is very well established in clinical series (Bramhall et al., 1996 (Bramhall et al., , 1997 Gress et al., 1995) , and it has recently been proposed as a potentially useful marker of prognosis if combined with other conventional markers like CA19-9 (Bramhall et al., 1997; Zhou et al., 1998) , this emphasises the importance of confirming gene expression data obtained by any method by at least one additional independent technique.
In this study we have detected several transcripts which have not been previously associated with pancreatic malignancy. ABL2 (Arg) belongs to the Abelson family of nonreceptor tyrosine kinases and is a close homologue of the c-abl oncogene (Kruh et al., 1990) . In addition to conserved catalytic domains common to all tyrosine protein kinases, they also contain highly homologous SH2 and SH3 domains. Carboxyl-terminal region of the two proteins contains several nuclear localization sequences, binding domains for G and F actin and RNA polymerase II CTDinteracting domain, but display less than 30% identity, which suggests only a partial overlap in the functions of the two genes (Baskaran et al., 1997) . The c-abl oncogene was previously implicated in various malignancies, but the involvement of ABL2 was only recently described in acute myeloid leukaemia carrying a t(1;12)(q25;p13) translocation (Cazzaniga et al., 1999) . In our study we have found increased transcript levels of ABL2 in neoplastic cells compared to their normal counterparts by cDNA array analysis and confirmed this finding by QRT -PCR, but the mechanism of this upregulation remains to be elucidated.
We have recently described expression of genes from the Wnt5a pathway in malignant cells isolated by aspiration from pancreatic adenocarcinomas (Crnogorac-Jurcevic et al., 2001) , and now in microdissected neoplastic cells we have found another developmentally regulated gene, Notch4, to be upregulated by both cDNA array experiments and QRT -PCR. The constitutively active intracellular domain of Notch4 (Int-3) has been shown to have oncogenic activity in the mouse mammary gland (Jhappan et al., 1992) , and a 1.8 kb RNA species (normally expressed only in testis) was described in human breast, lung and colon carcinoma cell lines (Imatani and Callahan, 2000) . Moreover, activation of ras signalling appears to be required for Notchmediated oncogenesis (Fitzgerald et al., 2000) . Notch signalling was also recently described as critical for the decision between the endocrine and exocrine fates in the developing pancreas (Apelqvist et al., 1999) . Its upregulation in pancreatic adenocarcinoma represents yet another example of involvement of developmental regulators in tumorigenesis in an adult organ.
Copper-zinc-superoxide dismutase (SOD1) is another gene that was found upregulated in microdissected malignant pancreatic epithelial cells, and this finding was confirmed by QRT -PCR. SOD1 is involved in elimination of superoxide radicals (O 27 ) and is one of the key enzymes that protects cells from damage induced by reactive oxygen species (ROS) (Bankson et al., 1993) . Although SOD1 activity seems to be variable depending on tumour type, increased levels were found in both human and mouse leukaemia cells in comparison to mature normal blood cells, and SV40-transformed WI-38 lung fibroblasts display higher SOD values than nascent cells (Oberley and Buettner, 1979; Westman and Marklund, 1981) . As SOD1 inhibition causes accumulation of O 27 and leads to mitochondrial membrane damage and release of cytochrome c, resulting in apoptosis, targeting of this molecule has recently been proposed as a potential therapeutic strategy for the selective killing of malignant cells (Huang et al., 2000) . CD59 (protectin) is a widely expressed regulator of complement activation. It inhibits complementmediated lysis by preventing the full assembly of the membrane attack complex (Maio et al., 1998) . CD59 upregulation is found in a high proportion of tumours examined (Maio et al., 1998) , including a study of eight pancreatic carcinomas (Schmitt et al., 1999) . We have now extended those data using our tissue array and found that almost 60% of tumours displayed intense immunoreactivity, in contrast to the moderate reactivity in the normal ductal cells (Figure  3b,c) .
One of the genes found downregulated in pancreatic cancer is the DNA repair gene XRCC1. It is involved in sister chromatid exchange and repair of singlestranded DNA breaks. It recognizes DNA breaks, binds the DNA and recruits other components of the repair machinery, namely polynucleotide kinase, DNA ligase III, DNA polymerase beta and poly(ADP-ribose) polymerase (PARP) (Rice, 1999; Whitehouse et al., 2001) .
Cigarette smoke is a rich source of chemical carcinogens and reactive oxygen species which induce DNA damage (including single-strand breaks), and smoking is the only environmental agent for which a positive correlation with pancreatic cancer development has been established in epidemiological studies (Gold, 1995) . Decreased XRCC1 transcript expression in pancreatic adenocarcinoma correlates with decreased expression of its protein product, as shown in our cDNA microarray and tissue array experiments. Immunohistochemical data clearly showed a marked difference between the staining intensity in normal and malignant ducts. The mechanism of XRCC1 downregulation has not yet been elucidated, but it is notable that in our previous study using spectral karyotyping to analyse a panel of 20 pancreatic carcinoma cell lines, seven showed deletions in 19q where the gene maps (Sirivatanauksorn et al., 2001) . It is likely that loss of XRCC1 function would enhance the genotoxic effects of exposure to carcinogens in cigarette smoke and other environmental factors, and so accelerate accumulation of further genetic abnormalities. In summary, the use of pure cell populations of both normal and malignant cells obtained by laser-assisted microdissection and a cancer-selective cDNA array in gene expression analysis enabled us to implicate fifteen differentially expressed genes, several of which have not previously been associated with pancreatic malignancy. The variety of genes described here illustrates the involvement of multiple pathways in the development of pancreatic adenocarcinomas and includes several new targets for further analysis in this malignant disease.
Materials and methods
Tissues and cell lines
Freshly frozen tissue blocks of three pancreatic adenocarcinomas and their corresponding normal counterparts were obtained from the Department of Pathology, University of Verona, Italy with full ethical approval from the host institution. Histologically, they were all well differentiated carcinomas of ductal phenotype and were used for expression profiling of laser-microdissected normal and neoplastic ductal cells.
Twenty freshly-frozen adenocarcinoma samples from Hospital Beaujon, Clichy, Paris, France and 16 pancreatic cell lines were used for real-time quantitative RT -PCR analysis. Cell lines included ASPC1, BxPC-3, CaPan1, CaPan2, HS766T, Mia PaCa-2, PANC-1 and SU86.86 obtained from the American Type Culture Collection (Rockville, MD, USA); PaTu 8988s and PaTu 8988t from Dr HF Kern (Department of Cell Biology, Philipps University, Marburg, Germany); PaCa44 from Dr M von Bu¨low (University of Mainz, Germany); PT45 from from Dr H Kalthoff (University of Kiel, Germany); T3M3 from Dr T Okabe (Tohoku University, Japan); HPAF from Dr R Metzger, (University of N. Carolina, Durham, NC, USA); PSN1 from Dr H Yamada (Jikei University School of Medicine, Tokyo, Japan); and HuP-T4 from Dr H Sasaki (Toyama University, Japan). All cell lines were cultured in E-4 medium (Media Production, Cancer Research UK, Clare Hall Laboratories, Middlesex, UK) supplemented with 10% heat-inactivated foetal calf serum (Gibco -BRL, Life Technologies, Paisley Scotland). As normal controls, three matched-to tumour normal tissues ( named 1N, 4N and 5N) , two donor pancreata not suitable for transplantation (2N and 3N) , a pool of normal pancreatic RNA samples (coded 6N) purchased from Clontech (Basingstoke, Hampshire, UK), and the normal pancreatic ductal cell line HPDE (coded 7N), a kind gift from Dr MS Tsao, University of Toronto (Furukawa et al., 1996) were used.
Microdissection and RNA isolation from normal and malignant tissues
Prior to microdissection, the quality of RNA from each tissue block was carefully assessed, because pancreatic tissue is extremely prone to autolysis due to its high enzyme content. Matched normal ductal cells and malignant glandular elements were microdissected from 8 mm thick cryosections with a Pixcell system (Arcturus Engineering, USA) with a laser beam set at 30 mm as described previously (CrnogoracJurcevic et al., 2002) .
The caps (Arcturus, Sunnyvale, USA) containing microdissected material were inserted directly into Eppendorf tubes containing TRIZOL reagent (Gibco -BRL, Life Technologies Inc., Frederick, MA, USA) and total RNA and DNA were isolated according to the manufacturer's protocol, except at the final step, where RNA was precipitated with the addition of linear acrylamide to 10 mg/ml (Ambion, AMS Biotechnology, Oxon, UK).
The integrity of RNA after microdissection was checked as follows: after procurement of the desired cells, the remaining tissue from the section was dissected using the 'shotgun mode' and the cap carrying this material inserted into a separate tube with the isolation buffer. This material was processed in parallel with microdissected normal and malignant ducts and the integrity of its RNA checked on small agarose gels using SYBRGold dye (Molecular Bioprobes, Eugene, OR, USA). This dye allows detection of RNA with a sensitivity approximately 10 times greater than the ethidium bromide staining method and enables visualization of RNA concentrations as low as 10 ng (two filled caps usually give a sufficient amount of material for clear visualization of 28S and 18S RNA bands -see insets in Figure 1 ). The quantity of RNA was assessed using the RiboGreen RNA Quantitation Kit (Molecular Probes, Eugene, OR, USA) in the low-range assay (1 ng/ml to 50 ng/ml) according to the protocol supplied. Dissection of approximately 15 sections and around 1610 4 cells resulted in a yield of 50 -100 ng of total RNA.
DNA isolated from the same samples was used for the mutation analysis of KRAS, TP53, CDKN2 and MADH4, the four most commonly altered genes in pancreatic adenocarcinomas, according to the protocols described earlier .
Labelling and hybridization
In order to increase the amount of material obtained by microdissection and reduce the effect of biological heterogeneity between tumour samples derived from different patients, 100 ng from each of the three microdissected cancer samples were pooled (as all cases had the same mutation profile, we did not expect any of them to display a severely different profile and adversely affect the profile of the whole pool). An equivalent pool was made with the matched normal ducts. Both pools were used as templates for PCR amplification using the SMART PCR cDNA synthesis kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol and 450 ng of amplified cDNA was labelled with a 32 P-dATP (3000 Ci/mmol; Amersham Pharmacia Biotech, UK) using CDS Primer Mix specific for the genes present on Clontech arrays according to the manufacturer's instructions. The membranes were hybridized overnight with 1.5610 6 c.p.m./ml of ExpressHyb hybridization solution (Clontech, Palo Alto, CA, USA) at 688C in a Hybaid roller bottle incubator. Membranes were washed twice with 26SSC/1% SDS and twice with 0.16SSC/0.5% SDS at 688C for 30 min each and the filters were exposed on phosphor storage screens for 3 days. They were scanned in a Molecular Dynamics phosphorimager and images stored for further analysis.
The SMART amplification procedure and hybridization experiments were performed in duplicate.
Data analysis
The quantitative data were obtained using AtlasImage 1.01a software (Clontech Laboratories, Palo Alto, CA, USA) that places a grid around the image, assigns a pixel value to each spot, subtracts the background and performs global normalization. A gene was considered to be expressed if the obtained pixel intensity was higher than twice the background level, and a twofold (0.5) difference was taken as the cut-off for scoring upregulated (or downregulated) expression.
Real-time quantitative RT -PCR
QRT -PCR was used as an independent method to confirm dysregulation of Notch4, ABL2 and SOD1. cDNAs were synthesized from 1 to 5 mg total RNA using an oligo dT primer and the Superscript II reverse transcription kit (Gibco -BRL, Life Technologies, Paisley, Scotland). The cDNAs were column-purified (Qiagen, Crawley, West Sussex, UK) and eluted at a concentration of 10 ng/ml. The primers used were: Notch4 sense, 5'-CCACCTATCAGGAGAGAG-CAGC-3'; Notch4 antisense, 5'-GGAACGACGCTACC-GACGTCAC-3'; ABL2 sense, 5'-GTGATGAGACTACTG-CAGCATCC-3'; ABL2 antisense, 5'-CGGTTACCGTG-TCGTCCATGAT-3'; SOD1 sense 5'-CTCACTCTCAGGA-GACCATTGC-3', SOD1 antisense 5'-CCGAACACCACA-TTAACCCTAG-3'.
These amplify a 185 bp Notch4 fragment, a 232 bp ABL2 fragment and a 142 bp SOD1 product. Reactions containing 10 ng cDNA, SYBR green sequence detection reagents (Oswel Research Products Ltd, Southampton, UK) and sense and antisense primers were assayed on an ABI7700 sequence detection system (Applied Biosystems). The PCR conditions were one cycle at 508C for 2 min, one cycle at 958C for 10 min and 40 cycles of 958C for 15 s, 658C (except for Notch4, 678C) for 1 min. The accumulation of PCR product was measured in real time as the increase in SYBR green fluorescence, and the data were analysed using the Sequence Detector program v1.6.3 (Applied Biosystems). Standard curves relating initial template copy number to fluorescence and amplification cycle were generated using the amplified PCR product as a template and were used to calculate gene copy number in each sample.
Tissue array construction and immunohistochemical analysis
The tissue array (TMA) was constructed from representative regions of 110 paraffin embedded samples including 93 pancreatic ductal adenocarcinomas, 12 normal pancreata matched to the tumour tissues, three normal pancreata from organ donors and two pancreatic neuroendocrine tumours. The paraffin blocks were obtained from Hospital Beaujon, Clichy, Paris, France, and TMA were constructed using the arrayer from Beecher Instruments (Silver Spring, MD, USA) as described previously (Kononen et al., 1998) . Two antibodies used in the study included mouse anti-human CD59 (1/50 dilution, Serotec, UK) and prediluted mouse monoclonal XRCC1 antibody (Lab Vision UK Ltd., Suffolk, UK).
Appropriate antibody dilutions and staining conditions were optimized on full tissue sections prior to using the tissue array. Both tissue array and whole-section slides were stained using techniques and reagents from DAKO (Glostrup, Denmark). The intensity of staining was graded on a scale from 0 to 3 and the extent of positive immunoreactivity was scored according to the percentage of stained cells (0 points for no staining, one point for 520%, two points for 20 -50% and three points for 450% of the cells). The total score was obtained as the product of intensity and extent of staining. Negative or weakly positive cases had a score of 0 -3, moderately positive had a score of 4 -6 and strongly positive cases had a final score greater than six. Statistical analysis was performed using the Fisher's exact test.
SAGE and DDD analysis
The publicly available SAGEmap (http://www.ncbi.nlm.nih. gov/SAGE) and Digital Differential Display (DDD) (http:// www.ncbi.nlm.nih.gov/Unigene) databases were used to confirm differential expression of genes obtained by cDNA array analysis. In DDD, four pooled pancreatic cancer libraries were compared to five pooled libraries from normal pancreas. In SAGE analysis, two libraries of normal pancreatic ductal cells (HX and H126), two bulk pancreatic cancer tissues (Panc91-6113 and Panc96-6252) and four pancreatic cancer cell lines (CAPAN1, CAPAN2, HS766T and PANC1) were examined.
In order to identify tags that were significantly overexpressed in the pancreatic cancer versus the normal ductal cells we have used a significance test specifically designed for the analysis of tag sampling data as described (Audic and Claverie, 1997) .
